PPARG and type 2 diabetes mellitus: Through a series of crystal structures we mechanistically show that a synthetic PPARγ ligand, including one used as an FDA-approved drug in the treatment of type 2 diabetes, pushes a bound endogenous UFA to an alternate site upon binding rather than completely displacing it.